Since PTHrP secretion by metastatic cells increases osteoblasts RANKL production and subsequent osteclastogenesis, the current prevailing view is that CaSR osteolytic potential comes from its ability to increase metastatic breast cancer cells PTHrP secretion. This evidence concerns the gene CASR and breast carcinoma.